Wanzhong Yixin Files IPO Prospectus: Building an Integrated 'Medical Care, Pharmaceuticals, Insurance, and Devices' Ecosystem for Hypertension Management
“Health management services are bundled with insurance. Wanzhong Yixin not only provides specialized medical health management services to hypertensive patients who have purchased health management packages, but also offers them complimentary hypertension-specific insurance.”
Effectively managing every hypertensive patient and reducing the incidence of hypertension-related complications can prevent patients from falling back into poverty due to illness, thereby alleviating the financial burden on both the national medical insurance system and households. This isWanzhong Yixin’s Ambitious Goal of Implementing the “Chronic Disease Management + Commercial Insurance” Model。
Professor Du Zuying, the company's founder, stated,Wanzhong Yixin has filled the gap in China’s health management and specialized insurance for chronic diseases such as hypertension by leveraging a comprehensive chronic disease health management system and collaborating with insurance companies, healthcare institutions, and pharmaceutical distribution enterprises.
According to the "Report on Cardiovascular Health and Diseases in China 2019," there are 330 million people with cardiovascular diseases in China, including nearly 300 million patients with hypertension. In light of this national context, the importance of chronic disease management has become increasingly prominent. Disease management should start at the primary care level, with medical institutions serving as the main force.
To address China’s large population of individuals with chronic diseases, the “Healthy China 2030” Planning Outline released in 2019 emphasized strengthening chronic disease screening and early detection, aiming to achieve comprehensive coverage of management and intervention for patients with hypertension and diabetes. By 2030, the goal is to realize chronic disease health management for the entire population across the full life cycle. Furthermore, the Outline calls for diversifying health insurance products and encourages the development of health insurance products linked to health management.
In 2020, Wanzhong Yixin Health Management Group was established in Beijing. The company’s founding mission is to address the unmet medical needs of patients with chronic diseases by drawing on the operational model of Kaiser Permanente in the United States, providing an integrated “health management services + insurance coverage” solution, and building a comprehensive chronic disease management ecosystem that integrates healthcare, pharmaceuticals, insurance, and medical devices.
In response to the "Outline of the Healthy China 2030 Plan,"Wanzhong Yixin has joined forces with multiple insurance companies (Taikang, China Reinsurance, China United Property Insurance, etc.), renowned medical institutions, and pharmaceutical distribution enterprises (China Resources, Jointown Pharmaceutical Group, etc.) to carry out the development and preparatory work for the “Hypertension Health Management Services + Insurance Products” initiative.。
In the course of collaborating with these enterprises, Wanzhong Yixin launched a chronic disease management service package, providing users with management focused primarily on hypertension, while also addressing blood lipid and blood glucose levels. The goal of this management is to bring patients’ blood pressure, blood glucose, and blood lipids within normal ranges, thereby preventing the occurrence of severe cardiovascular diseases. Meanwhile, Wanzhong Yixin has partnered with Taikang Insurance and China Reinsurance Group to develop insurance products specifically tailored for hypertensive patients, safeguarding their health.
Chronic diseases are characterized by prolonged duration, subtle onset, and complex etiologies. The vast majority are incurable, necessitating long-term, comprehensive management. In line with the national policy of “prioritizing primary care and emphasizing prevention,” chronic disease management should be implemented at the grassroots level, with community physicians or village doctors overseeing patient care.
Clinical outcomes confirm that hypertension in patients is preventable and controllable.Kaiser Permanente in the United States manages one million patients with hypertension, achieving a blood pressure control rate of 90%. In January 2017, the Chinese Academy of Medical Sciences launched the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) study, which was the first large-scale, nationwide, multicenter, randomized, open-label clinical trial in China targeting elderly hypertensive patients aged 60–79 years. As of October 2018, the overall control rate in the STEP study reached 90.6%. These achievements demonstrate that with well-planned and diligent chronic disease management, hypertension can be effectively controlled among patients in China.
To manage patients more effectively, Wanzhong Yixin’s health management service package covers the entire patient journey, encompassing management, treatment, rehabilitation, and insurance.In December 2020, Wanzhong Yixin obtained the qualification for a national internet hospital.The company’s health management program is rooted in primary care, encouraging and assisting primary care physicians in participating in the full-cycle care of patients.
Previously, primary care physicians mostly relied on office blood pressure measurements to assess patients' blood pressure status; however, office blood pressure readings are subject to many uncontrollable factors. Measurements taken when patients are anxious or not in a quiet state may yield inaccurate results. Therefore, long-term home blood pressure monitoring is crucial, as it provides accurate blood pressure data to physicians, facilitating medication adjustments.
The Wanzhong Yixin Platform will provide each user with a home blood pressure monitor capable of automatically uploading blood pressure data. It enables real-time monitoring, timely transmission, and data recording without the need for Bluetooth connectivity, allowing supervising family doctors to promptly assess patients’ blood pressure status and facilitate positive interaction between patients and physicians.
Furthermore, the backend management system issues different levels of alerts based on patients' abnormal blood pressure readings. The platform triggers a warning when a patient's blood pressure exceeds 150 mmHg and an alarm when it surpasses 180 mmHg. Meanwhile, the platform promptly pushes these abnormal blood pressure notifications to the attending physician's mini-program. Subsequently, the attending physician and backend customer service personnel will contact the patient or their family members as soon as possible to address the issue.Customer service representatives, back-end physicians, and attending physicians work as an integrated team to comprehensively ensure patient safety.
Through long-term blood pressure monitoring, the attending physician becomes familiar with the patient’s condition and can prescribe medications via the Wanzhong Yixin Internet Hospital platform, with CR Pharmaceutical delivering the drugs directly to the patient’s home. Wanzhong Yixin has established a strategic partnership with CR Pharmaceutical, leveraging its nationwide distribution network to ensure both drug quality and medication safety.
In addition to medical interventions for monitoring, diagnosis, and treatment, the platform routinely disseminates health information and organizes salon events to educate patients.Meanwhile, the platform also provides patients with recommendations on nutrition, exercise, and other aspects, with the aim of improving their daily lifestyles.
In addition, family members can also participate in the health management process. They can view the patient’s blood pressure data through the backend system to facilitate remote care, thereby forming a support system for hypertension patients.Multidimensional Management, patients, family members, physicians, and customer service representatives are all key components of health management.
Effective health management is inseparable from a high-caliber team of physicians; medical resources are the core of chronic disease management.
Wanzhong Yixin’s “Yixin Internet Hospital Management Platform” has onboarded nearly 30,000 physicians at the national, provincial, municipal, and county/district levels., and this number continues to grow. Physicians on the platform must undergo rigorous training and assessment; only those who have acquired sufficient medical knowledge and possess the corresponding competencies are permitted to manage patients.
To better serve patients and facilitate timely and effective disease management, the attending physician maintains a one-on-one interactive relationship with each patient.Once a patient enters the platform, a binding relationship is established between the patient and the physician.On WeChat Mini Programs, doctors and patients can communicate and consult via text, images, and voice messages.In addition, the platform stratifies patients based on their blood pressure status to help physicians identify those requiring prioritized attention. Furthermore, it generates weekly and monthly blood pressure statistics to prompt physicians to conduct follow-up visits and patient callbacks.
When encountering complex and challenging cases, primary care physicians can receive advice and guidance from senior physicians within the medical consortium. When patients require referral, Wanzhong Yixin will fully leverage medical resources at all levels, facilitating patient referrals in a stepwise manner from the county/district level to the national level. During the referral process, patients’ health records are documented, ensuring seamless continuity of medication histories, diagnostic tests, and medical records.
Hypertension can lead to many serious complications, such as cerebral hemorrhage, cerebral infarction, acute myocardial infarction, and renal failure, making it a high-risk condition. Consequently, most commercial insurance products on the market are not available to patients with hypertension, leaving these individuals and their families in a high-risk situation. Once severe complications arise, both families and society bear a substantial economic burden. According to China’s registered poverty household data, 44% of current impoverished households fall into poverty due to illness or disability.
Wanzhong Yixin adopts a dual strategy of chronic disease management and insurance. By implementing a comprehensive hypertension management system, it effectively reduces the incidence of severe cardiovascular diseases, thereby alleviating the financial burden on families and the national health insurance system, while achieving the public welfare objectives of specialized insurance and effective cost control.The integration of chronic disease management and insurance operations has established a virtuous cycle, creating a win-win scenario for patients and insurers. This synergy enables insurers to extend their services beyond mere post-claim reimbursement to comprehensive, end-to-end health management for their clients.
The company has established partnerships with China Reinsurance Group, Taikang Insurance Group, and others. In 2021, Wanzhong Yixin collaborated with China Reinsurance Group on a public welfare project in Xunhua County, Qinghai Province, jointly providing health management services to low-income residents and individuals with disabilities suffering from the “three highs” (hypertension, hyperglycemia, and hyperlipidemia) in the county. Currently, Wanzhong Yixin is conducting business in provinces and municipalities including Hebei, Jiangxi, Henan, and Hunan, aiming to achieve comprehensive sales of its hypertension management products.
According to VCBeat, the “Wanzhong Yixin” initiative has recently launched a fundraising round, with proceeds earmarked for the development of health insurance products, academic marketing and promotion, and expansion of its health services team.
The Internet-based chronic disease management market holds immense potential. According to the “2020 White Paper on Internet Chronic Disease Management in China,” the market size reached RMB 26.8 billion in 2020 and is projected to reach RMB 235.7 billion by 2025. How will Wanzhong Yixin take a solid step toward commercialization in this vast market by leveraging its “chronic disease management + insurance” model?